Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models

por Xu, Wenxin, Marcus, Warren D, Rhode, Peter R, Wong, Hing C
Publicado 2014

Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma

por Liu, Bai, Kong, Lin, Marcus, Warren D, Chen, Xiaoyue, Han, Kaiping, Rhode, Peter R, Wong, Hing C
Publicado 2014

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice

por Xu, Wenxin, Kage, Karen, Marcus, Warren D, Newman, Robby, Alter, Sarah, Rhode, Peter R, Wong, Hing C
Publicado 2015

Distinct molecular and cellular contributions to stabilizing selectin-mediated rolling under flow

por Yago, Tadayuki, Leppänen, Anne, Qiu, Haiying, Marcus, Warren D., Nollert, Matthias U., Zhu, Cheng, Cummings, Richard D., McEver, Rodger P.
Publicado 2002

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice

por Johnson, Christopher B, Riesenberg, Brian, Neitzke, Dan, Jeng, Emily K, Marcus, Warren D, Cole, David, Wong, Hing C, Rubinstein, Mark P
Publicado 2014

Novel antitumor mechanism-of-action of an IL-2 fusion protein mediated by tumor associated macrophage repolarization and innate-like CD8+ memory T cells

por Xu, Wenxin, Egan, Jack O, Liu, Bai, Chen, Xiaoyue, You, Lijing, Han, Kaiping, Marcus, Warren D, Kong, Lin, Jones, Monica, Jeng, Emily K, Rhode, Peter R, Wong, Hing C
Publicado 2014